Cyclic lipopeptide antibiotic

This page covers all Cyclic lipopeptide antibiotic drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Bacterial cell membrane.

Targets

Bacterial cell membrane

Marketed (2)

• daptomycin (up to 14 days) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Infectious Disease
  Daptomycin binds to bacterial cell membranes and causes rapid depolarization, leading to loss of essential ions and bacterial cell death.
• Daptomycin for Injection · Todd C. Lee MD MPH FIDSA · Infectious Disease
  Daptomycin disrupts bacterial cell membrane integrity by inserting into the lipid bilayer and causing depolarization and potassium efflux, leading to bacterial cell death.